Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06496607Phase 2Active Not Recruiting

A Study to Evaluate Solriktug in Adult Participants With Asthma

Role: lead

NCT06496620Phase 2Recruiting

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Role: lead

NCT06598462Phase 2Active Not Recruiting

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

Role: lead

NCT06868082Phase 1Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

Role: lead

NCT06640920Phase 1Completed

A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants

Role: lead

All 5 trials loaded